Streetwise Articles


News Update

Biotech's Antibodies Target Toxic Oligomers Implicated in Parkinson's Disease

News Update
  ()
Testing conducted as part of this Canadian company's research and development work on Parkinson's disease therapeutics has identified new potential antibody candidates. read more >

FDA Approves Biopharma's Drug with $1.75 Billion Peak Sales Potential

Research Report
  ()
An H.C. Wainwright & Co. report covered the greenlighting of two therapeutics developed by this firm, whose stock, according to the analyst, has more than fivebagger return potential. read more >

This Biotech Is 'Harnessing the Microbiome's Therapeutic Potential'

Research Report
  ()
A LifeSci Capital report presented a handful of key points about the firm. read more >

Texas Heart Takes to the CoreoGraft

Contributed Opinion
  ()
Daniel Carlson of Tailwinds Research profiles Hancock Jaffe Laboratories, which is partnering with the Texas Heart Institute to further develop an innovative graft designed for use in coronary bypass surgery. read more >
News Update

Developer of Nitric Oxide Delivery Devices Rebrands to Focus on Leading Advancements

News Update
  ()
This Utah-based company rolled out an online campaign that highlights its strategic repositioning. read more >

Company with Cancer Radiotherapy Grows Revenue for Six Consecutive Quarters

Research Report
  ()
An H.C. Wainwright & Co. report reviewed this company's Q4/18 earnings and opportunities for increasing it. read more >

Surgical Robotics Developer Demonstrates Technology at Medical Conference

Research Report
  ()
A Ladenburg Thalmann report relayed how this Massachusetts company participated at the Transcatheter Cardiovascular Therapeutics annual meeting through a live transmission—the first ever—of a remote interventional procedure using the CorPath GRX system. read more >

DURECT Receives Return on Schizophrenia Drug Approval

  ()
A new, once-monthly injectable treatment for schizophrenia uses patents of a small-cap, U.S.-based pharmaceutical firm. read more >

Stock in Vanguard of Drive to Phase Out Antibiotics in Animal Feed

Contributed Opinion
  ()
As the worldwide movement to ban antibiotics as a growth promoter in animal feed gains traction, technical analyst Clive Maund has called an "immediate strong buy" on a company that has developed an alternative. read more >
News Update

Life Sciences Company Hits Sales Milestone with Livestock Product

News Update
  ()
With this development, the Canadian firm entered a new geography and an additional market segment. read more >
News Update

Partnership Greenlighted for Canadian Biotech and Chinese Health Products Firm

News Update
  ()
This regenerative medicine company moves one step closer to commercialization of its cell therapies in East Asia. read more >

NIH Selects Biopharma's Lead Asset for Commercialization Accelerator Program

Research Report
  ()
A Maxim Group analyst reported on news and upcoming catalysts for this late-stage drug developer. read more >

Biotech's Preliminary Immunotherapy Data 'Positive,' Earns Coverage in Medical Journal

Research Report
  ()
An H.C. Wainwright & Co. report reviewed both the results and an "unusual" highlight from this firm's trial in head-and-neck cancer. read more >
News Update

Life Science Company Sells Large Order of Non-Antibiotic Growth Promoter for Livestock

News Update
  ()
This is the second large shipment to the Philippine distributor. read more >

This Company Has Better Numbers than Tilray at 1/25th the Price

Contributed Opinion
  ()
Tilray's wild fluctuations have grabbed the headlines the past few days, but Fincom Investment Partners profiles a rapidly emerging player in the cannabis realm that the firm believes has much more to offer. read more >

Coverage Initiated on 'Emerging Antibiotics Growth Story with Multiple Levers for Upside'

Research Report
  ()
An H.C. Wainwright & Co. report outlined the investment thesis for this U.S.-based biopharmaceutical firm. read more >

Cancer Vaccine Developer Expands Its Collaboration with Merck

Research Report
  ()
A Mackie Research Capital report tells how this biotech will benefit from its new and existing programs with this specific partner. read more >
Management Q&A: View from the Top

Medical Use of Nitric Oxide Expands as Costs Come Down

Managment Q&A: View from the Top
  ()
Dr. Brett Earl, a practicing physician and a vice president and director of Nu-Med Plus, discusses the many uses of nitric oxide and Nu-Med Plus' unique, low-cost delivery system. read more >
News Update

U.S. Biotech Partner Obtains Marketing Authorization for ADHD Treatment in Taiwan

News Update
  ()
Permission has been obtained to distribute time-release capsules. read more >

Why Tiny ITUS's CAR-T Therapy Could Be a Big Deal in Cancer Treatment

Contributed Opinion
  ()
With CAR-T being the hottest space in cancer therapy, Daniel Carlson of Tailwinds Research profiles an innovative company that has been collaborating with a major cancer center. read more >

Canadian Biopharma to Outlicense Pain Drug to South Korean Firm

Research Report
  ()
An Echelon Wealth Partners report discussed the deal terms. read more >

Biopharma's Positive FDA Meeting Outlines Path Forward for Trial

Research Report
  ()
A ROTH Capital Partners note explained the outcome of the tête-a-tête and its implications. read more >

Coverage Initiated on Firm with Paradigm-Shifting Colonoscopy Device

Research Report
  ()
A Ladenburg Thalmann report covered the asset, product market and financial projections of this Florida-based company. read more >

Final Approval of Biopharma's Lead Candidate Both Likely and Imminent

Research Report
  ()
A ROTH Capital Partners report provided the takeaways from a recent meeting with the management team for this company, which is targeting an orphan indication. read more >
News Update

Drug Company Receives $5 Million Milestone Payment

News Update
  ()
Company entitled to receive quarterly earn-out payments from patent agreement. read more >
Showing Results: 26 to 50 of 89 Prev Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts